|
|
|
|
|
|
|
|
Hi
MUTOMBO,
In the run up to Target TME ( 18-20 November,
Boston) I've had the chance to speak with and interview researchers
working on some of the hottest research projects in the field. One of
these projects is Noxxon Pharma’s NOX-A12.
NOX-A12
is a clinical candidate which inhibits CXCL12/SDF-1, which plays a key
role in homing and retention of leukemic cells to their protective
niches like the bone marrow or the lymph nodes. The biotech company has
had some promising results so far which may be of huge interest to you
and your work.
When I spoke to Anna Kruschinski, the project leader, she was able to go into much more detail for me:
|
|
|
|
|
|
|
|
|
|
|
|
“We
are in Phase II running two proof of concept studies in chronic
lymphocytic leukemia (CLL) and multiple myeloma (MM) using NOX-A12 in
combination with standard treatment, and we have managed to treat
approximately half of the required patients.”
I've made the full interview with Anna into a free downloadable PDF, where she discusses the clinical and PK/PD results they have seen already, as well as their future plans for taking NOX-A12 through the clinic. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
I hope you enjoy the interview and find the
content useful. Make sure you look out for updates as this week I will
be interviewing our chairman Michael Lisanti, Professor and Director, Breakthrough Breast Cancer Centre.
Best wishes,
Emma
Emma Hosgood
Programme Director
Hanson Wade
|
|
No comments:
Post a Comment